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Abstract
Background: Severe malaria is a medical emergency with high mortality. Prompt achievement of therapeutic
concentrations of highly effective anti-malarial drugs reduces the risk of death. The aim of this study was to assess
the pharmacokinetics and pharmacodynamics of intravenous artesunate in Ugandan adults with severe malaria.
Methods: Fourteen adults with severe falciparum malaria requiring parenteral therapy were treated with 2.4 mg/kg
intravenous artesunate. Blood samples were collected after the initial dose and plasma concentrations of artesunate
and dihydroartemisinin measured by solid-phase extraction and liquid chromatography-tandem mass spectrometry.
The study was approved by the Makerere University Faculty of Medicine Research and Ethics Committee (Ref2010-015)
and Uganda National Council of Science and Technology (HS605) and registered with ClinicalTrials.gov (NCT01122134).
Results: All study participants achieved prompt resolution of symptoms and complete parasite clearance with median
(range) parasite clearance time of 17 (8–24) hours. Median (range) maximal artesunate concentration (Cmax) was 3260
(1020–164000) ng/mL, terminal elimination half-life (T1/2) was 0.25 (0.1-1.8) hours and total artesunate exposure (AUC)
was 727 (290–111256) ng·h/mL. Median (range) dihydroartemisinin Cmax was 3140 (1670–9530) ng/mL, with Tmax of 0.14
(0.6 – 6.07) hours and T1/2 of 1.31 (0.8–2.8) hours. Dihydroartemisinin AUC was 3492 (2183–6338) ng·h/mL. None of the
participants reported adverse events.
Conclusions: Plasma concentrations of artesunate and dihydroartemisinin were achieved rapidly with rapid and
complete symptom resolution and parasite clearance with no adverse events.
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Background
Severe malaria is a medical emergency which if not treated
results in 100% mortality. Mortality reduces to 15–20%
with prompt, effective anti-malarial treatment and sup-
portive care [1]. It is fundamental that plasma concentra-
tions of a highly effective anti-malarial drug are achieved
as rapidly as possible. Two classes of drugs are available
for treatment of severe malaria; cinchona alkaloids, such
as quinine, and artemisinin derivatives, such as artemether
and artesunate.
Artesunate is a water-soluble hemisuccinate artemisinin
derivative; available as sodium hemisuccinate salt for injec-
tion (Guilin Pharmaceutical Factory, Guangxi, People’s
Republic of China). It has superior anti-malarial properties
to quinine and artemether and studies have demonstrated
a dramatic reduction in in-hospital mortality among chil-
dren and adults treated with artesunate [2-7]. Very recent
evidence strongly recommends intravenous artesunate as
treatment of choice for severe falciparum malaria world-
wide [1,2]. Artesunate’s excellent anti-malarial properties
demonstrated by rapid parasite and fever clearance, is
* Correspondence: pbyakika@idi.co.ug
1Infectious Diseases Institute, Makerere University, P. O. Box 22418, Kampala,
Uganda
2Department of Pharmacology and Therapeutics Trinity College, Dublin,
Ireland
Full list of author information is available at the end of the article
© 2012 Byakika-Kibwika et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Byakika-Kibwika et al. Malaria Journal 2012, 11:132
http://www.malariajournal.com/content/11/1/132
enhanced by its rapid hydrolysis to its active metabolite
dihydroartemisinin [8-14].
Data on artesunate and dihydroartemisinin pharmacoki-
netic profiles have been reported in healthy volunteers
[9,15,16] and patients with malaria [8,10,12,17-19] mainly
in south-east Asia. However, data in African patients, who
bear the brunt of malaria, are scarse. This study aimed to
investigate the pharmacokinetics and pharmacodynamics
of intravenous artesunate in Ugandan adults with severe
malaria.
Methods
Study design and participants
Fourteen adults with severe malaria, admitted to Mulago
National Referral Hospital, Kampala, Uganda were enrolled.
Participants were enrolled consecutively if they were
18 years of age and above, with a positive blood smear for
Plasmodium falciparum mono-infection, no other obvious
cause of the fever or symptoms, with at least one laboratory
or clinical feature of severe malaria and requiring parenteral
therapy in accordance with the 2010 World Health
Organization Guidelines [1]. Pregnant women, patients with
history of anti-malarial intake within the last 72 hours and
those receiving any herbal medication, known inhibitors or
inducers of cytochrome P450 were excluded.
The study was approved by the Makerere University
Faculty of Medicine Research and Ethics Committee
(Ref2010-015) and Uganda National Council of Science and
Technology (HS605) and registered with ClinicalTrials.gov
(NCT01122134). Study procedures were explained to parti-
cipants or their guardians in the local languages and infor-
mation leaflets were provided. All participants provided
written informed consent prior to enrollment.
Study procedures
Participants were admitted to Mulago Hospital for treat-
ment and monitoring. On admission, all participants
received baseline evaluation including; thorough history,
physical examination and laboratory investigations. All par-
ticipants were weighed and blood samples were collected by
finger-prick for malaria smears and venepuncture for haem-
atocrit, plasma lactate, glucose, renal and liver function
tests.
All participants received intravenous artesunate at a
dose of 2.4 mg/kg at time 0, 2.4 mg/kg at 12 hours and
2.4 mg/kg/daily until they could tolerate oral therapy.
Artesunate was dispensed in a 60-mg ampoule which
was dissolved in 1 mL of 5% sodium bicarbonate to form
sodium artesunate and diluted with 5 mL of 5% dex-
trose. The dose was injected as a slow bolus into an
indwelling intravenous cannula over 3–4 minutes. Sup-
portive therapy was given according to national malaria
treatment guidelines. When participants could tolerate
oral therapy, anti-malarial therapy was completed with a
full three-day course of oral artemether-lumefantrine
(Coartem®, Novartis Pharma AG, Basel, Switzerland).
Participants administered oral therapy as unsupervised
therapy at home but were given instructions to adminis-
ter it with food or milk.
Serial thick blood films and measurement of parasite
densities were performed until parasites were cleared
following the schedule; 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 18,
20, 24 hours and every six hours till six hours post-parasite
clearance. Blood smears were stained with 2% Giemsa for
thirty minutes and parasite densities calculated by count-
ing the number of asexual parasites per 200 white blood
cells (WBC) using the patient’s actual WBC count per uL
of blood.
Blood for artesunate and dihydroartemisinin assays was
drawn after the initial dose of artesunate in chilled fluor-
ide-oxalate tubes from the arm opposite that used for drug
administration at 0 (pre-dosing), 5, 10, 15, 30, 45 minutes,
1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dosing. The twelfth
hour sample was drawn pre-the twelve hour IV artesunate
dose. Four mL of venous blood were collected at each sam-
pling time. Blood samples were chilled immediately and
transported to the laboratory on ice to avoid artesunate
and dihydroartemisinin degradation. Samples were cen-
trifuged within 30 minutes and the plasma was stored
below −80°C until shipment on dry ice to the Clinical
Pharmacology Laboratory at the Mahidol-Oxford Trop-
ical Medicine Research Unit in Thailand for artesunate
and dihydroartemisinin quantification. The maximum
duration of sample storage was approximately three
months at −80°C.
Complete physical examination was performed daily
for each patient. Vital signs were monitored and
recorded every four hours until parasite clearance. Parti-
cipants were discharged home when they were afebrile,
aparasitaemic and able to take oral therapy. They
returned one week after discharge for review of symp-
toms, clinical examination and a repeat blood smear.
Assessment of adverse events was performed on admis-
sion and 1 week post discharge using history and phys-
ical examination.
Artesunate and dihydroartemisinin quantification
The plasma concentrations of artesunate and dihydroarte-
misinin were determined using solid-phase extraction and
liquid chromatography-tandem mass spectrometry on an
API 5000 triple-quadrupole mass spectrometer (Applied
Biosystems/MDS SCIEX, Foster City, CA) with a TurboV
ionization source operated in the positive ion mode [17].
Stable isotope-labelled artesunate and stable isotope-
labelled dihydroartemisinin were used as internal stan-
dards. Total assay coefficients of variation for artesunate
and dihydroartemisinin were <5% for inter- and intraday
precisions. The lower limits of quantification (LLOQ) for
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artesunate and dihydroartemisinin were set at 1.2 and
2.0 ng/mL, respectively.
Pharmacokinetic and statistical analysis
Pharmacokinetic analysis was performed with WinNonlin
software, version 5.2 (Pharsight Corp., Mountain View, CA,
USA) using an infusion non-compartmental analysis
model. Complete bioconversion of artesunate to dihydroar-
temisinin was assumed. Calculated parameters included
maximal observed concentration (Cmax), terminal elimin-
ation half-life (T1/2), total exposure measured as area under
the plasma concentration-time curve (AUClast) from the
start of drug infusion until the last quantifiable observation,
elimination clearance (CL) and apparent volume of distri-
bution (V). The AUC was calculated by application of the
trapezoidal rule (linear-up/log-down). All parameters were
calculated using time in hours after the time of first drug
administration (T = 0). Drug concentrations below the
LLOQ of the bioanalytical assays were treated as missing
data.
Data were analysed using STATA® version 10.0 (Stata-
Corp, College Station, TX). Baseline characteristics were
summarized into medians with interquartile range (IQR).
Pharmacokinetic parameters were summarized into med-
ians with range. Parasite clearance time was defined as the
time taken to clear all parasites from circulation ie time
until the first of two sequential negative thick blood smears.
Results
A total of 14 adults (9, 64% female) admitted with severe
malaria were enrolled. At admission participants, had
been ill for a median (IQR) of 7 (3 – 7) days. One par-
ticipant had been ill for 14 and another 21 days. Some
participants had more than one feature of severe malaria
as follows two (14%) reported severe vomiting, five (36%)
had jaundice, two (14%) had extreme weakness with in-
ability to sit or stand, 10 (71%) were severely dehydrated,
one (7%) had hyperpyrexia and one (7%) had haemo-
globinuria. Median (range) parasite density at baseline
was 18867 (500–79,950) parasites/μL. All participants
received acetaminophen (paracetamol) for fever and pain
relief. No other medications outside the study were
administered. Baseline clinical and laboratory character-
istics of study participants at admission are shown in
Table 1.
Clinical response
All study participants tolerated artesunate very well and
reported very rapid recovery from symptoms and ability
to take oral medication after 24 hours. No immediate ad-
verse events were recorded. The median (range) parasite
clearance time was 17 (8 – 24) hours. Individual plots of
parasite density against time post start of treatment are
shown in Figure 1. Blood smears for all participants
remained negative for malaria parasites at one week post
discharge from hospital. Only one patient had gameto-
cytes at baseline and these cleared within 4 hours after
start of treatment.
Pharmacokinetics of artesunate and dihydroartemisinin
Pharmacokinetic parameters and profiles for artesunate
and dihydroartemisinin are summarized in Table 2 and
Figure 2. Following the intravenous administration, arte-
sunate was detected in plasma very promptly rising to
the Cmax within a median (range) of 0.09 (0.6 – 6.07)
hours.
It was cleared fast with median (range) elimination T1/2
of 0.25 (0.11 – 1.82) hours. Participants achieved the Cmax
for dihydroartemisinin within a median (range) of 0.14
(0.6 – 6.07) hours post dose administration (Table 2).
There was no correlation between total artesunate or total
dihydroartemisinin exposure with parasite clearance times
(Spearman’s rho correlation coefficient −0.12 and −0.18
respectively).
Discussion
This study aimed to investigate the pharmacokinetics
and pharmacodynamics of intravenous artesunate in
adults with severe falciparum malaria. Following intra-
venous administration of artesunate, study participants
achieved plasma concentrations of artesunate and dihy-
droartemisinin very promptly. All participants achieved
rapid parasite clearance with prompt resolution of symp-
toms and no adverse events.
High plasma concentrations of artesunate and dihy-
droartemisinin were achieved and artesunate was rapidly
cleared from circulation. The Cmax for artesunate and
Table 1 Baseline clinical and laboratory characteristics of
study participants
Parameter Median (IQR)
Age (years) 24.0 (20.0–35.0)
Weight (kgs) 56.3 (54–62.5)
Height (m) 1.7 (1.6–1.7)
BMI 20 (18.8–23.3)
Axillary temperature (0 C) 37.1 (36.5–38.8)
Respiratory rate ( per minute) 24.0 (24.0–26.0)
Pulse rate ( per minute) 106 (95–113)
Systolic blood pressure (mmHg) 114 (106–128)
Diastolic blood pressure (mmHg) 73 (69–82)
Hemoglobin (mg/dl) 12.9 (11.2–14.2)
Plasma creatinine (g/dl) 63.5 (54–75)
Serum bilirubin (μmol/L) 30 (15.2–87.6)
Serum lactate (mmol/L) 3.25 (1.9–4.1)
Blood sugar (mmol/L) 4.8 (4.4–6.1)
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dihydroartemisinin were observed rapidly post-dose
administration indicating rapid conversion of artesunate to
dihydroartemisinin. Artesunate was cleared from circula-
tion rapidly while dihydroartemisinin had a longer elimin-
ation T1/2. Previous studies have attributed the
effectiveness of artesunate to its high initial Cmax and rapid
and extensive hydrolysis to dihydroartemisinin [8,14,18].
Although the peak concentration of artesunate was
higher than that of dihydroartemisinin, total exposure to
dihydroartemisinin was more than four times that of
artesunate. The pharmacokinetic parameters observed in
the present study are similar to findings from previous
studies [8,10,11,14]. Both artesunate and dihydroartemi-
sinin concentrations and AUC varied markedly among
participants. This marked variability is similar to data
from a previous study [19], however, despite the very
large inter-individual variability all patients had very
rapid parasite clearance. Parasite clearance time was
comparable to that from a previous study [11] and
shorter than a median of 66 hours from other studies
[19,20]. The differences are possibly due to differences in
parasite sensitivity or baseline parasitaemia.
Although a previous study suggested a trend of an
association between artesunate and dihydroartemisinin
AUC and parasite clearance [11]; the present study did
not find this. The study by Newton et al, also demon-
strated no relationship between artesunate pharmacoki-
netic parameters and parasiticidal effect [19]. It is not
clear which artesunate pharmacokinetic parameter best
correlates with anti-malarial treatment effect, but previ-
ous dose finding studies have suggested doses higher
than 2 and 2.4 mg/kg as the minimum initial dose for
malaria treatment in view of the considerable inter-
Figure 1 Individual plots of parasite density against time post start of treatment.
Table 2 Pharmacokinetic parameters of artesunate and
dihydroartemisinin
Parameter Artesunate Dihydroartemisinin
Median (range) Median (range)
Dose (mg) 140 (111–190) 103 (82–140)
Cmax (ng/mL) 3260 (1020–164000) 3140 (1670–9530)
Tmax (hr) 0.25 (0–6.07) 0.14 (0–6.07)
CL (L/hr) 180 (1–652) 32.25 (16–55)
V (L) 68.5 (0.18–818) 59.7 (26–117)
T1/2 (hr) 0.25 (0.11–1.82) 1.31 (0.89–2.87)
AUC0-last (ng·h/mL) 727 (290–111256) 3492 (2183–6338)
Figure 2 Mean artesunate and dihydroartemisinin plasma
concentration versus time. Vertical bars represent standard error.
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individual variability in artesunate pharmacokinetic
profile [19,20].
This study contributes to the existing knowledge on
the clinical response to and pharmacokinetics of intra-
venous artesunate for treatment of severe malaria. Previ-
ous studies have demonstrated superiority of intravenous
artesunate over intravenous quinine for severe malaria
treatment [2,3]. These data strongly suggest that paren-
teral artesunate should be considered the drug of first
choice in treating severe malaria [2,3]. Compared to arte-
sunate, quinine has a number of disadvantages including
poor compliance and a significant adverse event profile
like hypotension, hypoglycaemia and gastro-intestinal
intolerance [21,22]. The intravenous quinine infusion is
difficult and expensive to institute and needs constant
monitoring for arrhythmia and hypoglycaemia. Adher-
ence to the eight-hourly regimen of intravenous quinine
is poor especially in resource-limited settings and often
patients do not complete the dose increasing the risks
for treatment failure and development of drug resistance.
The high patient-nurse ratio and lack of facilities for the
IV infusion in health centers and hospitals in resource-
limited settings lead to inappropriate and incorrect
methods of quinine administration [23]. The ease of
bolus intravenous administration plus the lack of a sig-
nificant side effect profile make intravenous artesunate
an excellent choice for use in very remote peripheral
centers that suffer the greatest brunt of severe malaria.
However, parenteral artesunate is not yet widely available
and affordable especially in sub-Saharan Africa, where
the greatest burden of severe malaria and death occurs
and efforts to improve accessibility should be reinforced.
Conclusions
Plasma concentrations of artesunate and dihydroartemi-
sinin were achieved rapidly with rapid and complete
symptom resolution and parasite clearance with no ad-
verse events.
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